share_log

華領醫藥-B：截至2024年12月31日止年度的年度業績公告

HUA MEDICINE-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024

HKEX ·  Mar 27 08:42

Summary by Moomoo AI

華領醫藥2024財年營收達人民幣2.559億元，同比增長234%，主要受益於华堂宁®被納入國家醫保目錄後銷量大增。年內銷售約210.5萬盒华堂宁®，產品已進入中國內地約2,700家醫院。截至2024年底，公司持有現金11.4億元，資產負債表保持穩健。公司於2025年1月1日起全面接管华堂宁®在中國內地的商業化任務，並聘請具20年糖尿病藥物商業化經驗的陸宇先生負責銷售及市場工作。2025年首兩個月，华堂宁®銷量約59.2萬盒，銷售淨額約7,320萬元，同比增長199%，顯示商業化交接順利且成效顯著。公司積極推進國際市場佈局，已完成第二代GKA在美國的SAD研究，驗證其對2型糖尿病及肥胖患者的治療可行性。同時，基於人類遺傳資料研究顯示，dorzagliatin對糖尿病相關併發症具有潛在獲益，包括減少心臟衰竭、冠狀動脈疾病等。公司將繼續投資擴大產能，以滿足2026年及2027年的預期市場需求。
華領醫藥2024財年營收達人民幣2.559億元，同比增長234%，主要受益於华堂宁®被納入國家醫保目錄後銷量大增。年內銷售約210.5萬盒华堂宁®，產品已進入中國內地約2,700家醫院。截至2024年底，公司持有現金11.4億元，資產負債表保持穩健。公司於2025年1月1日起全面接管华堂宁®在中國內地的商業化任務，並聘請具20年糖尿病藥物商業化經驗的陸宇先生負責銷售及市場工作。2025年首兩個月，华堂宁®銷量約59.2萬盒，銷售淨額約7,320萬元，同比增長199%，顯示商業化交接順利且成效顯著。公司積極推進國際市場佈局，已完成第二代GKA在美國的SAD研究，驗證其對2型糖尿病及肥胖患者的治療可行性。同時，基於人類遺傳資料研究顯示，dorzagliatin對糖尿病相關併發症具有潛在獲益，包括減少心臟衰竭、冠狀動脈疾病等。公司將繼續投資擴大產能，以滿足2026年及2027年的預期市場需求。
Hualing Pharmaceutical's revenue for the fiscal year 2024 reached 0.2559 billion yuan, a year-on-year increase of 234%, mainly benefiting from the significant sales increase after Huatangning® was included in the national medical insurance catalog. During the year, approximately 2.105 million boxes of Huatangning® were sold, and the product has entered about 2,700 hospitals in mainland China. As of the end of 2024, the company holds 1.14 billion yuan in cash, and the balance sheet remains robust.The company will fully take over the commercialization of Huatangning® in mainland China from January 1, 2025, and has appointed Mr. Lu Yu, who has 20 years of experience in the commercialization of diabetes medications, to lead the sales and marketing efforts. In the first two months of 2025, sales of Huatangning...Show More
Hualing Pharmaceutical's revenue for the fiscal year 2024 reached 0.2559 billion yuan, a year-on-year increase of 234%, mainly benefiting from the significant sales increase after Huatangning® was included in the national medical insurance catalog. During the year, approximately 2.105 million boxes of Huatangning® were sold, and the product has entered about 2,700 hospitals in mainland China. As of the end of 2024, the company holds 1.14 billion yuan in cash, and the balance sheet remains robust.The company will fully take over the commercialization of Huatangning® in mainland China from January 1, 2025, and has appointed Mr. Lu Yu, who has 20 years of experience in the commercialization of diabetes medications, to lead the sales and marketing efforts. In the first two months of 2025, sales of Huatangning® amounted to approximately 0.592 million boxes, with net sales of about 73.2 million yuan, a year-on-year increase of 199%, indicating a smooth and effective commercialization handover.The company is actively advancing its international market layout, having completed the SAD study of the second generation GKA in the USA, validating its feasibility for treating type 2 diabetes and obesity patients. At the same time, research based on human genetic data shows that dorzagliatin has potential benefits for diabetes-related complications, including reducing heart failure and coronary artery disease. The company will continue to invest in expanding production capacity to meet the expected market demand for 2026 and 2027.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 271

Recommended

Market Insights

Market Hot Picks Market Hot Picks
No. Symbol Price
Tesla
TSLA
268.460
NVIDIA
NVDA
110.150
Newsmax
NMAX
233.000
4
CoreWeave
CRWV
52.570
5
Palantir
PLTR
84.680
Log In for the Full List
Unlock Now

Discussing

Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina Show More
Can strong earnings reports drive Chinese concept stocks to continue rising?
78%
22%
Bullish
Bearish
1556 votes
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
On Tuesday, China's political leadership is convening at the Great Hall of the People in Beijing for the year's most significant event, known as the "Two Sessions." These closed-door meetings are the annual plenary sessions of both the National People's Congress and the Chinese People's Political Consultative Conference, typically held simultaneously in March. The sessions generally last for about ten days....

Discussing

FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma Show More
Fed rate cut expectations for 2025 intensify. What’s your market outlook?
44%
56%
Bullish
Bearlish
1579 votes
FOMC Press Conference, March 19, 2025

- No more -

Statement

This page is machine-translated. Moomoo tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
OK